本文選題：血必凈注射液 + 慢性阻塞性肺疾病急性加重�。� 參考：《遼寧中醫(yī)藥大學》2017年碩士論文

【摘要】：目的:通過觀察血必凈注射液對痰瘀互結型慢性阻塞性肺疾病急性加重治療前后臨床癥狀、二氧化碳分壓、氧分壓、炎性因子及免疫細胞的改善情況,探討血必凈的臨床療效。材料與方法:收入2015年1月至2017年2月期間于沈陽市解放軍第四六三醫(yī)院呼吸科住院的痰瘀互結型的慢性阻塞性肺疾病急性加重患者(肺功能診斷為慢性阻塞性肺疾病重度且加重誘因為感染引起)70人,男性36人,女性34人,將70名急性加重患者隨機分為血必凈組及對照組,血必凈組35人,其中男性16人,女性19人,平均年齡69.23±5.29歲.對照組35人,男性20人,女性15人,平均年齡68.94±5.99歲。經χ2檢驗,對兩組患者性別、年齡、肺功能進行統(tǒng)計分析,無統(tǒng)計學差異(P0.05),具有可比性。對照組給予常規(guī)吸氧、祛痰、解痙、抗感染治療,血必凈組在對照組的基礎上加用血必凈注射液,治療時間為7天。7天后比較兩組患者咳嗽、咳痰等臨床癥狀、二氧化碳分壓(Pa CO2)、氧分壓(Pa O2)、外周血白細胞計數(shù)(WBC)、血清降鈣素原(PCT)、超敏C反應蛋白(Hs-CRP)、血沉(ESR)、白細胞介素-6(IL-6)、輔助性T淋巴細胞(CD4+)、抑制性T淋巴細胞(CD8+)及CD4+/CD8+比率比值的變化情況。結果:1.血必凈組治療后咳嗽、咳痰等臨床癥狀改善情況優(yōu)于對照組,血必凈組總有效率94.3%,對照組總有效率85.7%,具有統(tǒng)計學意義(P0.05)。2.血必凈組治療后Pa O2含量高于對照組,Pa CO2的含量低于對照組,血必凈組療效優(yōu)于對照組,具有統(tǒng)計學意義(P0.05)。3.血必凈組治療后外周血WBC、血清PCT、Hs-CRP、ESR、IL-6的改善情況優(yōu)于對照組,具有統(tǒng)計學意義(P0.05)。4.血必凈組治療后外周血T淋巴細胞CD4+較對照組升高,CD8+較對照組降低,CD4+/CD8+比值升高優(yōu)于對照組,具有統(tǒng)計學意義(P0.05)。結論:1.常規(guī)基礎治療上加用血必凈注射液可改善慢性阻塞性肺疾病急性加重患者臨床癥狀,提高療效。2.常規(guī)基礎治療上加用血必凈注射液能提高慢性阻塞性肺疾病急性加重患者血氧含量,改善缺氧狀態(tài)。3.常規(guī)基礎治療上加用血必凈注射液能改善慢性阻塞性肺疾病急性加重患者外周血WBC、血清PCT、Hs-CRP、ESR、IL-6等炎性指標,提高患者治療效果。4.常規(guī)基礎治療上加用血必凈注射液能提高慢性阻塞性肺疾病急性加重患者免疫功能,提高免疫力。
[Abstract]:Objective: to observe the improvement of Xuebijing injection on clinical symptoms, partial pressure of carbon dioxide, partial pressure of oxygen, inflammatory factors and immune cells before and after treatment of acute exacerbation of chronic obstructive pulmonary disease with phlegm and blood stasis. Materials and methods: from January 2015 to February 2017, patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) who were hospitalized in respiratory department of the 463rd Hospital of the Chinese PLA in Shenyang from January 2015 to February 2017 were diagnosed as chronic obstructive pulmonary disease (COPD). The lung disease was severe and aggravated. 70 people were infected with it. Thirty-six males and 34 females were randomly divided into Xuebijing group (n = 35) and control group (n = 35). There were 16 males and 19 females with an average age of 69.23 鹵5.29 years. Control group 35, male 20, female 15, average age 68.94 鹵5.99 years old. The sex, age and lung function of the two groups were statistically analyzed by 蠂 2 test. There was no statistical difference between the two groups (P 0.05). The control group was given routine oxygen inhalation, expectorant, spasmolysis, anti-infection treatment, and Xuebijing group was treated with Xuebijing injection on the basis of the control group. The treatment time was 7 days, and the clinical symptoms such as cough, expectoration and phlegm were compared between the two groups. Paco _ 2, CO _ 2, CO _ 2, WBC, PCT, Hs-CRP, ESR, IL-6IL-6, helper T lymphocyte CD4, suppressive T lymphocyte CD8) and CD4 / CD8 ratio The change of the ratio. The result is 1: 1. The improvement of cough, expectoration and other clinical symptoms in Xuebijing group was better than that in control group. The total effective rate of Xuebijing group was 94.30.The total effective rate of control group was 85.7g, which had statistical significance. After treatment, the content of Pao 2 in Xuebijing group was higher than that in control group, and the content of Pa CO2 in Xuebijing group was lower than that in control group. In Xuebijing group, the improvement of peripheral blood WBCand serum PCTX Hs-CRP ESRN IL-6 was better than that of control group, which had statistical significance (P 0.05). Compared with the control group, the CD4 of peripheral blood T lymphocytes in Xuebijing group was higher than that in the control group, and the decrease of CD4 / CD8 ratio was higher than that in the control group, which had statistical significance (P 0.05). Conclusion 1. Routine basic treatment plus Xuebijing injection can improve the clinical symptoms of patients with acute exacerbation of chronic obstructive pulmonary disease. Routine basic treatment with Xuebijing injection can increase the blood oxygen content in patients with acute exacerbation of chronic obstructive pulmonary disease and improve anoxic state. 3. Routine basic therapy with Xuebijing injection can improve the peripheral blood WBCand serum PCT Hs-CRPU ESR-IL-6 in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). Routine basic therapy with Xuebijing injection can improve the immune function and immunity of patients with acute exacerbation of chronic obstructive pulmonary disease.
【學位授予單位】：遼寧中醫(yī)藥大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R563.9

【參考文獻】

相關期刊論文 前10條

1 張琪;石克華;;中醫(yī)藥治療慢性阻塞性肺疾病急性加重期研究進展[J];亞太傳統(tǒng)醫(yī)藥;2017年07期

2 刁云鋒;張士俊;趙萬勇;孫洪濤;張賽;孫亮;;血必凈注射液對重癥肺炎患者血漿IL-6和TNF-α水平的影響[J];中草藥;2017年06期

3 韓寧;朱姝;;楊濤主任醫(yī)師活血化瘀法治療慢性阻塞性肺疾病經驗初探[J];中國中醫(yī)藥現(xiàn)代遠程教育;2017年06期

4 陳立文;李崇文;;不同病程COPD患者免疫功能的臨床分析[J];中國實驗診斷學;2017年01期

5 王蕾;楊汀;王辰;;2017年版慢性阻塞性肺疾病診斷、處理和預防全球策略解讀[J];中國臨床醫(yī)生雜志;2017年01期

6 李筱筱;武雪玲;賈世亮;戴雪伶;孫雅煊;;丹參酮ⅡA藥理作用的研究進展[J];生物學雜志;2016年06期

7 張愛妹;萬引;;慢性阻塞性肺疾病患者T淋巴細胞亞群表達及意義分析[J];當代醫(yī)學;2016年34期

8 王蕾;馮笑山;毛毅敏;張劍青;孫瑜霞;張英民;吳丹;戴路明;;COPD患者血清炎癥介質水平在病情評估中的應用價值[J];中國地方病防治雜志;2016年11期

9 胡曉琳;戴曉彬;柯正華;Q鎂，

本文編號：1941900